ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Quick facts
Phase 3 pipeline
- IMM01 · Oncology
IMM01 is an immunotherapeutic agent designed to enhance anti-tumor immune responses, likely through modulation of immune checkpoint pathways or T-cell activation.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. portfolio CI brief
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc. pipeline updates RSS
Frequently asked questions about ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s pipeline?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has 1 drugs in Phase 3, 2 in Phase 2, 5 in Phase 1. Late-stage candidates include IMM01.
Related
- Sector hub: All tracked pharma companies